Health Care & Life Sciences » Pharmaceuticals | HanAll Biopharma Co. Ltd.

HanAll Biopharma Co. Ltd. | Mutual Funds

Mutual Funds that own HanAll Biopharma Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total International Stock Index Fund
511,924
0.98%
0
0%
07/31/2018
iShares Core MSCI Emerging Markets ETF
273,906
0.52%
0
0.02%
09/05/2018
Government Pension Fund - Global (The)
236,159
0.45%
1,973
0%
12/31/2017
Vanguard Developed Markets Index Fund
205,710
0.39%
0
0.01%
07/31/2018
Mirae Asset TIGER 200
122,562
0.24%
13,943
0.12%
01/31/2018
Vanguard FTSE All World (ex-US) Small Cap
88,595
0.17%
0
0.04%
07/31/2018
Mirae Asset TIGER Health Care ETF
66,034
0.13%
15,797
1.26%
04/30/2018
iShares Plc - Core MSCI Emerging Markets IMI UCITS ETF
53,080
0.1%
0
0.02%
09/05/2018
Mirae Asset TIGER Consumer Staples ETF
48,445
0.09%
-30,050
0.74%
04/30/2018
Vanguard Pacific Stock Index Fund
40,068
0.08%
0
0.02%
07/31/2018

About HanAll Biopharma Co.

View Profile
Address
43 Sangseodang 1-gil
Daejeon DE 34344
Korea, Republic Of
Employees -
Website http://www.hanall.co.kr
Updated 07/08/2019
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceutical. Its products include medicine for digesting, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.